{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:24Z","timestamp":1787020824362,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["9039-00015B"],"award-info":[{"award-number":["9039-00015B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008368","name":"Gigtforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>During treatment with immune checkpoint inhibitors (ICI) such as the anti-PD-1 antibody pembrolizumab, half of patients with pre-existing inflammatory arthritis experience disease flares. The underlying immunological mechanisms have not been characterized. Here, we investigate the effect of pembrolizumab on cells involved in inflammation and destruction in the synovial joint and how immunosuppressive treatments affect the pembrolizumab-induced immune reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included synovial fluid mononuclear cells (SFMCs,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928) and peripheral blood mononuclear cells (PBMCs,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) from patients with rheumatoid arthritis and peripheral spondyloarthritis and PBMCs from healthy controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096). Fibroblast-like synovial cells (FLSs) were grown from SFMCs. The in vitro effect of pembrolizumab was tested in SFMCs cultured for 48\u2009h, FLS-PBMC co-cultures and in SFMCs cultured for 21\u2009days (inflammatory osteoclastogenesis). Cells and supernatants were analyzed by ELISA, flow cytometry, and pro-inflammatory multiplex assay. Finally, the effect of the disease-modifying anti-rheumatic drugs (DMARDs) adalimumab (TNF\u03b1 inhibitor), tocilizumab (IL-6R inhibitor), tofacitinib (JAK1\/JAK3 inhibitor), and baricitinib (JAK1\/JAK2 inhibitor) on pembrolizumab-induced immune reactions was tested.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pembrolizumab significantly increased monocyte chemoattractant protein-1 (MCP-1) production by arthritis SFMCs (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0031) but not by PBMCs from patients or healthy controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.77 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.43). Pembrolizumab did not alter MMP-3 production in FLS-PBMC co-cultures (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.76) or TRAP secretion in the inflammatory osteoclastogenesis model (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.28). In SFMCs, pembrolizumab further increased the production of TNF\u03b1 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0110), IFN\u03b3 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0125), IL-12p70 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0014), IL-10 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0100), IL-13 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0044), IL-2 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0066), and IL-4 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0008) but did not change the production of IL-6 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.1938) and IL-1 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.1022). The SFMCs treated with pembrolizumab showed an increased frequency of intermediate monocytes (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.044), and the MCP-1 production increased only within the intermediate monocyte subset (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.028). Lastly, adalimumab, baricitinib, and tofacitinib treatment were able to attenuate the pembrolizumab-induced MCP-1 production (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0004,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.033, and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.025, respectively), while this was not seen with tocilizumab treatment (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.75).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pembrolizumab specifically activated intermediate monocytes and induced the production of several cytokines including TNF\u03b1 but not IL-6. These findings indicate that flares in patients with pre-existing inflammatory arthritis involve monocyte activation and could be managed with TNF\u03b1 neutralization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-022-02737-6","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T02:02:59Z","timestamp":1644804179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis"],"prefix":"10.1186","volume":"24","author":[{"given":"Anne Sofie","family":"S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten N\u00f8rgaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Juul-Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie Dyrelund","family":"Broks\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e6cilie","family":"Skej\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vorup-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-397X","authenticated-orcid":false,"given":"Tue Wenzel","family":"Kragstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"2737_CR1","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol (Hoboken, NJ). 2019;71:2100\u201311. https:\/\/doi.org\/10.1002\/art.41068.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2737_CR2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England J Med. 2012;366:2455\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1200694.","journal-title":"New England J Med"},{"key":"2737_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England J Med. 2012;366:2443\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1200690.","journal-title":"New England J Med"},{"key":"2737_CR4","doi-asserted-by":"publisher","first-page":"e000321","DOI":"10.1136\/rmdopen-2016-000321","volume":"2","author":"LC Cappelli","year":"2016","unstructured":"Cappelli LC, Shah AA, Bingham CO 3rd. Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open. 2016;2:e000321. https:\/\/doi.org\/10.1136\/rmdopen-2016-000321.","journal-title":"RMD Open"},{"key":"2737_CR5","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.3892\/ol.2017.6919","volume":"14","author":"S Stucci","year":"2017","unstructured":"Stucci S, et al. Immune-related adverse events during anticancer immunotherapy: pathogenesis and management. Oncol Letters. 2017;14:5671\u201380. https:\/\/doi.org\/10.3892\/ol.2017.6919.","journal-title":"Oncol Letters"},{"key":"2737_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.cir-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A, et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res. 2016;4:194\u2013203. https:\/\/doi.org\/10.1158\/2326-6066.cir-15-0210.","journal-title":"Cancer Immunol Res"},{"key":"2737_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","volume":"42","author":"EJ Lipson","year":"2015","unstructured":"Lipson EJ, et al. Antagonists of PD-1 and PD-L1 in cancer treatment. Sem Oncol. 2015;42:587\u2013600. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.05.013.","journal-title":"Sem Oncol"},{"key":"2737_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/annrheumdis-2017-211649","volume":"77","author":"B Smiljanovic","year":"2018","unstructured":"Smiljanovic B, et al. Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint. Ann Rheumatic Dis. 2018;77:300\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211649.","journal-title":"Ann Rheumatic Dis"},{"key":"2737_CR9","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","volume":"118","author":"KL Wong","year":"2011","unstructured":"Wong KL, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011;118:e16\u201331. https:\/\/doi.org\/10.1182\/blood-2010-12-326355.","journal-title":"Blood"},{"key":"2737_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/art.20219","volume":"50","author":"M Iwahashi","year":"2004","unstructured":"Iwahashi M, et al. Expression of toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheumatism. 2004;50:1457\u201367. https:\/\/doi.org\/10.1002\/art.20219.","journal-title":"Arthritis Rheumatism"},{"key":"2737_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1189\/jlb.0806510","volume":"81","author":"L Ziegler-Heitbrock","year":"2007","unstructured":"Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81:584\u201392. https:\/\/doi.org\/10.1189\/jlb.0806510.","journal-title":"J Leukoc Biol"},{"key":"2737_CR12","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/rheumatology\/kes304","volume":"52","author":"JL Davignon","year":"2013","unstructured":"Davignon JL, et al. Targeting monocytes\/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford, England). 2013;52:590\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kes304.","journal-title":"Rheumatology (Oxford, England)"},{"key":"2737_CR13","doi-asserted-by":"publisher","first-page":"e109775","DOI":"10.1371\/journal.pone.0109775","volume":"9","author":"BR Yoon","year":"2014","unstructured":"Yoon BR, et al. Functional phenotype of synovial monocytes modulating inflammatory T-cell responses in rheumatoid arthritis (RA). PLoS One. 2014;9:e109775. https:\/\/doi.org\/10.1371\/journal.pone.0109775.","journal-title":"PLoS One"},{"key":"2737_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/rheumatology\/40.6.673","volume":"40","author":"Y Suzuki","year":"2001","unstructured":"Suzuki Y, et al. Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology (Oxford, England). 2001;40:673\u201382. https:\/\/doi.org\/10.1093\/rheumatology\/40.6.673.","journal-title":"Rheumatology (Oxford, England)"},{"key":"2737_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14397595.2017.1369491","volume":"28","author":"S Tanaka","year":"2018","unstructured":"Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, Takeuchi T. RANKL: a therapeutic target for bone destruction in rheumatoid arthritis. Modern Rheumatol. 2018;28:9\u201316. https:\/\/doi.org\/10.1080\/14397595.2017.1369491.","journal-title":"Modern Rheumatol"},{"key":"2737_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381. https:\/\/doi.org\/10.1002\/art.27584.","journal-title":"Arthritis Rheum"},{"key":"2737_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, et al. The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25\u201331. https:\/\/doi.org\/10.1136\/ard.2010.133645.","journal-title":"Ann Rheum Dis"},{"key":"2737_CR18","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"key":"2737_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41927-018-0036-5","volume":"2","author":"S Lomholt","year":"2018","unstructured":"Lomholt S, Mellemkjaer A, Iversen MB, Pedersen SB, Kragstrup TW. Resveratrol displays anti-inflammatory properties in an ex vivo model of immune mediated inflammatory arthritis. BMC Rheumatol. 2018;2:27. https:\/\/doi.org\/10.1186\/s41927-018-0036-5.","journal-title":"BMC Rheumatol"},{"key":"2737_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cei.12577","volume":"180","author":"TW Kragstrup","year":"2015","unstructured":"Kragstrup TW, et al. Toll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activity. Clin Exp Immunol. 2015;180:233\u201342. https:\/\/doi.org\/10.1111\/cei.12577.","journal-title":"Clin Exp Immunol"},{"key":"2737_CR21","doi-asserted-by":"publisher","first-page":"1759720X1982866","DOI":"10.1177\/1759720X19828669","volume":"11","author":"TW Kragstrup","year":"2019","unstructured":"Kragstrup TW, et al. IL-12\/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19828669. https:\/\/doi.org\/10.1177\/1759720X19828669.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2737_CR22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/cyto.a.22995","volume":"89","author":"MN Andersen","year":"2016","unstructured":"Andersen MN, Al-Karradi SN, Kragstrup TW, Hokland M. Elimination of erroneous results in flow cytometry caused by antibody binding to fc receptors on human monocytes and macrophages. Cytometry. 2016;89:1001\u20139. https:\/\/doi.org\/10.1002\/cyto.a.22995.","journal-title":"Cytometry"},{"key":"2737_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jim.2004.11.023","volume":"297","author":"B Jahrsdorfer","year":"2005","unstructured":"Jahrsdorfer B, Blackwell SE, Weiner GJ. Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes. J Immunol Methods. 2005;297:259\u201363. https:\/\/doi.org\/10.1016\/j.jim.2004.11.023.","journal-title":"J Immunol Methods"},{"key":"2737_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/cei.12973","volume":"189","author":"TW Kragstrup","year":"2017","unstructured":"Kragstrup TW, et al. Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis. Clin Exp Immunol. 2017;189:342\u201351. https:\/\/doi.org\/10.1111\/cei.12973.","journal-title":"Clin Exp Immunol"},{"key":"2737_CR25","doi-asserted-by":"publisher","first-page":"e0148486","DOI":"10.1371\/journal.pone.0148486","volume":"11","author":"TW Kragstrup","year":"2016","unstructured":"Kragstrup TW, et al. Changes in soluble CD18 in murine autoimmune arthritis and rheumatoid arthritis reflect disease establishment and treatment response. PLoS One. 2016;11:e0148486. https:\/\/doi.org\/10.1371\/journal.pone.0148486.","journal-title":"PLoS One"},{"key":"2737_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/acr2.11094","volume":"2","author":"MA Nielsen","year":"2020","unstructured":"Nielsen MA, et al. Responses to cytokine inhibitors associated with cellular composition in models of immune-mediated inflammatory arthritis. ACR Open Rheumatol. 2020;2:3\u201310. https:\/\/doi.org\/10.1002\/acr2.11094.","journal-title":"ACR Open Rheumatol"},{"key":"2737_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-016-0964-7","volume":"18","author":"TW Kragstrup","year":"2016","unstructured":"Kragstrup TW, et al. The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression. Arthritis Res Ther. 2016;18:61. https:\/\/doi.org\/10.1186\/s13075-016-0964-7.","journal-title":"Arthritis Res Ther"},{"key":"2737_CR28","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1186\/ar4471","volume":"16","author":"TW Kragstrup","year":"2014","unstructured":"Kragstrup TW, et al. Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis. Arthritis Res Ther. 2014;16:R42. https:\/\/doi.org\/10.1186\/ar4471.","journal-title":"Arthritis Res Ther"},{"key":"2737_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/03009742.2013.823517","volume":"43","author":"SR Greisen","year":"2014","unstructured":"Greisen SR, et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol. 2014;43:101\u20138. https:\/\/doi.org\/10.3109\/03009742.2013.823517.","journal-title":"Scand J Rheumatol"},{"key":"2737_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","volume":"6","author":"KF Moseley","year":"2018","unstructured":"Moseley KF, et al. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. J Immunother Cancer. 2018;6:104. https:\/\/doi.org\/10.1186\/s40425-018-0417-8.","journal-title":"J Immunother Cancer"},{"key":"2737_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Annals Rheum Dis. 2017;76:43\u201350. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209595.","journal-title":"Annals Rheum Dis"},{"key":"2737_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/acr2.1026","volume":"1","author":"J Albayda","year":"2019","unstructured":"Albayda J, Dein E, Shah AA, Bingham CO 3rd, Cappelli L. Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: a case series. Acr Open Rheumatol. 2019;1:303\u20137. https:\/\/doi.org\/10.1002\/acr2.1026.","journal-title":"Acr Open Rheumatol"},{"key":"2737_CR33","doi-asserted-by":"publisher","first-page":"1632902","DOI":"10.1155\/2018\/1632902","volume":"2018","author":"Q Xia","year":"2018","unstructured":"Xia Q, et al. Immune checkpoint receptors Tim-3 and PD-1 regulate monocyte and T lymphocyte function in septic patients. Mediat Inflamm. 2018;2018:1632902. https:\/\/doi.org\/10.1155\/2018\/1632902.","journal-title":"Mediat Inflamm"},{"key":"2737_CR34","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1126\/science.1698311","volume":"249","author":"SD Wright","year":"1990","unstructured":"Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (New York, NY). 1990;249:1431\u20133. https:\/\/doi.org\/10.1126\/science.1698311.","journal-title":"Science (New York, NY)"},{"key":"2737_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/art.33418","volume":"64","author":"M Rossol","year":"2012","unstructured":"Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 2012;64:671\u20137. https:\/\/doi.org\/10.1002\/art.33418.","journal-title":"Arthritis Rheum"},{"key":"2737_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-016-1216-6","volume":"19","author":"M Tsukamoto","year":"2017","unstructured":"Tsukamoto M, et al. CD14(bright)CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Res Ther. 2017;19:28. https:\/\/doi.org\/10.1186\/s13075-016-1216-6.","journal-title":"Arthritis Res Ther"},{"key":"2737_CR37","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.intimp.2018.10.016","volume":"65","author":"AK Rana","year":"2018","unstructured":"Rana AK, Li Y, Dang Q, Yang F. Monocytes in rheumatoid arthritis: circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol. 2018;65:348\u201359. https:\/\/doi.org\/10.1016\/j.intimp.2018.10.016.","journal-title":"Int Immunopharmacol"},{"key":"2737_CR38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/intimm\/dxz036","volume":"31","author":"S Hirose","year":"2019","unstructured":"Hirose S, Lin Q, Ohtsuji M, Nishimura H, Verbeek JS. Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis. Int Immunol. 2019;31:687\u201396. https:\/\/doi.org\/10.1093\/intimm\/dxz036.","journal-title":"Int Immunol"},{"key":"2737_CR39","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.4049\/jimmunol.1601281","volume":"198","author":"M Chimen","year":"2017","unstructured":"Chimen M, et al. Monocyte subsets coregulate inflammatory responses by integrated signaling through TNF and IL-6 at the endothelial cell interface. J Immunol. 2017;198:2834\u201343. https:\/\/doi.org\/10.4049\/jimmunol.1601281.","journal-title":"J Immunol"},{"key":"2737_CR40","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3389\/fimmu.2019.02035","volume":"10","author":"TS Kapellos","year":"2019","unstructured":"Kapellos TS, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 2019;10:2035. https:\/\/doi.org\/10.3389\/fimmu.2019.02035.","journal-title":"Front Immunol"},{"key":"2737_CR41","doi-asserted-by":"publisher","first-page":"vii49","DOI":"10.1093\/rheumatology\/kez360","volume":"58","author":"J Leipe","year":"2019","unstructured":"Leipe J, Mariette X. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. Rheumatology (Oxford, England). 2019;58:vii49\u201358. https:\/\/doi.org\/10.1093\/rheumatology\/kez360.","journal-title":"Rheumatology (Oxford, England)"},{"key":"2737_CR42","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u201368. https:\/\/doi.org\/10.1200\/jco.2017.77.6385.","journal-title":"J Clin Oncol"},{"key":"2737_CR43","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","volume":"76","author":"ST Kim","year":"2017","unstructured":"Kim ST, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76:2061\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211560.","journal-title":"Ann Rheum Dis"},{"key":"2737_CR44","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25:551\u20137. https:\/\/doi.org\/10.1177\/1078155217745144.","journal-title":"J Oncol Pharm Pract"},{"key":"2737_CR45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.ccr-18-2795","volume":"25","author":"SY Lim","year":"2019","unstructured":"Lim SY, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res. 2019;25:1557\u201363. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-2795.","journal-title":"Clin Cancer Res"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02737-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02737-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02737-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T02:11:55Z","timestamp":1644804715000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02737-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2737"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02737-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"16 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All samples were obtained after informed written consent according to the declaration of Helsinki and approved by the Local Ethics committee (Central Denmark Region, project number: 20121329) and the Danish Data Protection Agency.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"TWK has engaged in educational activities presenting in topics on immunology in rheumatic diseases receiving speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, and UCB and has received a consultancy fee from Bristol-Myers Squibb. TWK is co-founder and clinical developer in iBiotech ApS developing diagnostic and therapeutic solutions for people with autoimmune diseases and cancer. TV-J taught in a training course for health care professionals on the side effects of ICIs and was paid an honorarium by Roche. The rest of the authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}